Special Issue

Advances in Nanoparticle-Based Therapeutics: From Extracellular Vesicles to Metal Nanocarriers for Cancer Therapy

Message from the Guest Editor

Cancer remains one of the most complex and aggressive diseases of our time, demanding targeted therapeutic strategies. Over the past decade, two converging fields—extracellular vesicle (EV) biology and metal-based nanotechnology—have opened new frontiers in cancer therapy.

Extracellular vesicles, the body's natural messengers, are potent drug delivery vehicles, capable of transporting therapeutic molecules with high specificity and low immunogenicity. Engineered metal-based nanocarriers, such as gold, silver, and iron oxide nanoparticles, offer platforms with precise control over drug release, imaging, and multifunctional targeting.

This Special Issue explores the interface between these approaches, featuring research into EV biogenesis, engineering, and the design of metal nanocarriers. The goal is to combine biological precision and material innovation to overcome limitations in cancer treatment.

By highlighting advances, challenges, and translational perspectives, this Special Issue aims to foster collaboration across disciplines and drive the next generation of cancer therapeutics.

Guest Editor

Prof. Dr. Eleni K. Efthimiadou

Inorganic Chemistry Laboratory, Department of Chemistry, National and Kapodistrian University of Athens, 15771 Zografou, Greece

Deadline for manuscript submissions

31 December 2025



an Open Access Journal by MDPI

Impact Factor 5.5 CiteScore 10.0 Indexed in PubMed



mdpi.com/si/245251

Pharmaceutics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceutics@mdpi.com

mdpi.com/journal/pharmaceutics





an Open Access Journal by MDPI

Impact Factor 5.5 CiteScore 10.0 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceutics and biopharmaceutics. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

Editor-in-Chief

Prof. Dr. Patrick J. Sinko

Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, William Levine Hall, Room 225C, 160 Frelinghuysen Road, Piscataway, NJ 08854-8020, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 14.9 days after submission; acceptance to publication is undertaken in 3.3 days (median values for papers published in this journal in the first half of 2025).

